Revolutionary stem cell technology for unmet medical needs
Our lifetime endeavor remains to fight human diseases with no effective cure.
This is especially true when patients face life-threatening medical conditions and chronic diseases. Inspired, our mission has focused on establishing a new paradigm in regenerative medicine.
After over a decade of research at Stanford University — we did just that, with a radical breakthrough in stem cell technology - Adult High-Plasticity Stem Cells (AHPSCs™).
We obtained the worldwide exclusive IP license from Stanford University and established a dedicated facility to further our proprietary research.
APstem Therapeutics is a proud member of the StartX community.
The APstem Team
At APstem Therapeutics, we are deeply united in our mission… an unwavering dedication to overcoming the greatest health challenges of our time using Adult High-Plasticity Stem Cells (AHPSCs™).
Min Hu MD, PhD
Founder, CEO
and President
Dr. Min Hu has more than 20 years of experience in the fields of stem cell biology, gene therapy and regenerative medicine.
[read more]
From a scientist at Stanford University to a leader of a biotech company, Dr. Hu has accumulated solid background knowledge and first-hand experience of clinical cell therapies as well as business operation.
Shaowei Li MD
Co-Founder, CSO
and Vice President
Prior to joining APstem Therapeutics, Dr. Shaowei Li conducted stem cell research at Stanford University for well over 10 years.
[read more]
Dr. Li has broad knowledge and expertise in the stem cell field and biological experiments as well as in clinical treatments. His studies focus on development of new and effective stem cell products and therapies.
Bowen Liu PhD
Co-Founder, COO
and Director of IP
Before joining APstem Therapeutics, Dr. Bowen Liu was at Sheppard Mullin Richter & Hampton LLP, an AmLaw 100 law firm.
[read more]
There, she worked on patent prosecution and IP-related matters. She received her Ph.D. in Cellular and Molecular Pathology from University of Pittsburgh and her B.S. in Biological Science from Tsinghua University. She has also conducted post-doctoral research at Stanford University.
Bo (Eric) Liu, MS
Director of Pre-clinical Study
Bo (Eric) Liu has over ten years of lab management experience and research experience of in vivo models and studies.
[read more]
Prior to joining APstem Therapeutics, Eric managed and oversaw research labs and vivarium at Stanford University.
Alexandra Capela, PhD
Translational and Regulatory Consultant
Dr. Alexandra Capela has over 14 years of pre-clinical research and industry experience in stem cell therapies and translational projects.
[read more]
She has extensive regulatory expertise on several IND submissions.
Lanying Song, MD, PhD
Histopathology Consultant
Dr. Lanying Song has been a histopathologist for over 20 years, with experience in both academia and hospital settings.
[read more]
Her focus is on clinical diagnosis and preclinical histopathological analysis.
Advisory Board
Jane Lebkowski,
PhD
Dr. Lebkowski is an internationally recognized leader in the development of cell and gene-based therapies.
[read more]
She has direct management experience in the multi-disciplinary functions required to translate research discoveries to therapeutic products.
Jonathan Lakey,
Ph.D., MSM
Dr. Lakey is a world-renowned diabetes and islet transplantation expert and co-developer of the Edmonton Protocol…
[read more]
an international treatment for type 1 diabetes. Dr. Lakey is currently a Professor Emeritus in Departments Surgery and Biomedical Engineering at University of California Irvine. Dr. Lakey served as Director of the Clinical Islet Program in the Department of Surgery and Director of the Department of Surgery Stem cell laboratory. He has received numerous awards for his achievements in transplantation research and sits on the Scientific Advisory Boards for several diabetes and biotechnology companies, on regulatory boards establishing safety standards for cell and tissue transplantation, and on editorial boards of diabetes, biomaterial and transplantation journals. Dr. Lakey is widely sought as a speaker in the field of diabetes, islet transplantation and biomaterials in transplantation. His recent focus on stem cells and peptides has advanced the scientific methods and protocols used today.
George Michalopoulos, MD, PhD
Dr. Michalopoulos is a pioneer in the study of molecular pathways involved in liver regeneration.
[read more]
As chairman of the Pathology Department at UPMC, Dr. Michalopoulos is in charge of the hospitals’ laboratories and the processing and diagnosis of biopsy materials.
Tho Pham,
MD
Dr. Pham is Clinical Associate Professor at Stanford University and Chief Medical Officer at Stanford Blood Center.
[read more]
He also serves as Scientific Committee Co-Chair for the California Blood Bank Society (CBBS) and a member of American Association of Blood Banks (AABB). Dr. Pham is board certified by American Board of Pathology, Blood Banking/Transfusion Medicine and Anatomic and Clinical Pathology.
Alexander Reyzelman, DPM
Dr. Reyzelman is board certified in Podiatric Surgery and Professor at the California School of Podiatric Medicine at Samuel Merritt University.
[read more]
He founded Bay Area Foot Care in 1998 (as President), Center for Clinical Research in 2003 (as CEO), and Center for Limb Preservation at UCSF in 2011 (as Co-Director). Dr. Reyzelman is a member of the American College of Foot and Ankle Surgeons, American Podiatric Medical Association, and California Podiatric Medical Association.
JC Neel,
PhD
Dr. Neel has more than 15 years of experience in the fields of cutting-edge cell and molecular biology and neuroscience.
[read more]
Equipped with an international education from ParisTech M.Sc. (France), McGill University Ph.D. (Canada) and UCSF PostDoc (California), Dr. Neel worked in multiple biotech companies from enzymatic DNA synthesis at DNA Script to brain machine interface at Neuralink Corp. He also advised startups in gene therapy and biomanufacturing. Dr. Neel leads healthcare and biotech investments at Notley Bioscience.
Michael Siani-Rose
.
Michael Siani-Rose has over 20 years of experience in the fields of regenerative medicine, biotechnology and bioinformatics.
[read more]
He is currently a project management consultant to Big Pharma/Biotech, directing projects that reach broadly across manufacturing organizations.